CARDIFF ONCOLOGY, INC. Lessee, Operating Lease, Liability, to be Paid, Year Four
CARDIFF ONCOLOGY, INC. (CRDF) had Lessee, Operating Lease, Liability, to be Paid, Year Four of $136.00 thousand as of 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour · last filed 2024-02-29
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Four $136.00K.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Four $796.00K.
- 2022-09-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $796.00K.
- 2022-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Four $796.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Four |
|---|---|
| 2023-12-31 | $136.00K 10-K · filed 2024-02-29 |
| 2022-12-31 | $796.00K 10-K · filed 2023-03-02 |
| 2022-09-30 | $796.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $796.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $796.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $775.00K 10-K · filed 2022-02-24 |
| 2021-09-30 | $775.00K 10-Q · filed 2021-11-04 |
| 2020-03-31 | $3.42K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $3.42K 10-K · filed 2020-02-27 |
| 2019-09-30 | $5.87K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $5.87K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $5.87K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |